Contents. Approved by: Kent Lewandrowski, M.D. 6/1/2005 Written/Updated by: Gino Pagnani Date: 4/3/09



Similar documents
Chapter. Guaiac Screening CHAPTER 4: GUAIAC TESTING SCREENING FOR OCCULT BLOOD. Page 1 of 5 Guaiac doc 6/24/2005

OneStep Fecal Occult Blood RapiDip InstaTest. Cat #

CRMC Laboratory Draw Station is located in the Out Patient Services area. We are available 6AM to 6PM daily.

FECAL & GASTRIC OCCULT BLOOD TEST

Vaginal ph Test (ph Hydrion TM Paper )

URINE DIPSTICK Multistix 10SG

Vitamin C Content of Fruit Juice

Gastrointestinal Bleeding

Contents. POCT Program Massachusetts General Hospital - Pathology Service 55 Fruit Street, Boston, MA 02114

Chapter 14 Urinalysis, Body Fluids and Other Specimens. Objectives:

Vitamin C Content of Foods

Presence and extent of fatty liver or other metabolic liver diseases

COLORECTAL CANCER SCREENING

The degree of liver inflammation or damage (grade) Presence and extent of fatty liver or other metabolic liver diseases

General. What is a laboratory test? What is a waived test?

ANALYSIS OF VITAMIN C

Script/Notes for PowerPoint Presentation. Medication Use Safety Training for Seniors (MUST for Seniors)

Over the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada

Colorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society

Colorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society

STEP-BY-STEP INSTRUCTIONS FOR INVESTIGATIONAL USE. Rapid HCV Antibody Test FOR ORAQUICK RAPID HCV ANTIBODY TEST

A. Ketorolac*** B. Naproxen C. Ibuprofen D. Celecoxib

Unaccredited Point-of-Care Laboratory Testing Guideline for Physicians

Thank you very much for your interest in the Flu-FOBT Toolkit and Guide!

Blood Transfusion. Red Blood Cells White Blood Cells Platelets

SAMPLE PROCEDURE , 09/11

Urinalysis Compliance Tools. POCC Webinar January 19, 2011 Dr. Susan Selgren

Blood Transfusion. There are three types of blood cells: Red blood cells. White blood cells. Platelets.

Peptic Ulcer. Anatomy The stomach is a hollow organ. It is located in the upper abdomen, under the ribs.

IgM ELISA. For the quantitative determination of IgM in human serum and plasma. For Research Use Only. Not For Use In Diagnostic Procedures.

experiment5 Understanding and applying the concept of limiting reagents. Learning how to perform a vacuum filtration.

Parent & Healthcare Professional Instructions for the collection of Maternal & Umbilical Cord Blood

PREMIER PLASTIC SURGERY CENTER OF NEW JERSEY 310 MADISON AVENUE, SUITE 100, MORRISTOWN, NJ PHONE: FAX:

Division of Laboratory Medicine Department of Pathology and Laboratory Medicine Hospital of the University of Pennsylvania

Assessment Day Bariatric Surgery DePaul Drive, Suite 310 Bridgeton, MO (P) ssmweightloss.com

XV.Quality Assurance in the Blood Bank

Dry Ice Color Show Dry Ice Demonstrations

UW MEDICINE PATIENT EDUCATION. Xofigo Therapy. For metastatic prostate cancer. What is Xofigo? How does it work?

Daily aspirin therapy: Understand the benefits and risks

Blood-Based Cancer Diagnostics

Title: Glucose Testing: StatStrip Glucose Meter Page 1 of 6

Biohazardous Waste Management Plan

Particularly Hazardous Substances (PHS) Standard Operating Procedure (SOP)

TAKING CARE OF YOUR RHEUMATOID ARTHRITIS

Preventive services process, Practice Solutions. Generating reminder letters with MD verification

UCLA Henry Samueli School of Engineering and Applied Science STANDARD OPERATING PROCEDURE MEDICAL WASTE (BIOHAZARD WASTE) MANAGEMENT

Planning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation

IDENTIFICATION OF POLYMERS 1998 by David A. Katz. All rights reserved

Intraperitoneal Chemotherapy

Reconstitution of Solutions

Objectives At the completion of this module, unlicensed assistive personnel (UAP) should be able to:

Lipids. There are 2 types of lipids; those that contain the structural component of a fatty acid; and

ILLINOIS DEPARTMENT OF CENTRAL MANAGEMENT SERVICES CLASS SPECIFICATION CLINICAL LABORATORY TECHNICIAN SERIES

VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS

Calcium , The Patient Education Institute, Inc. nuf40101 Last reviewed: 02/19/2013 1

Vitamin C Titration to Survive a High Seas Journey ND Lights

If you are signing for a minor child, you refers to your child throughout the consent document.

The Facts on Equine Drug Testing

Michigan Electrical Employees Health Plan Benefits & Eligibility-at-a Glance Supplement to Medicare - Medicare Enrollees

Use of stents in esophageal cancer" Hans Gerdes, M.D. Director, GI Endoscopy Unit Memorial Sloan-Kettering Cancer Center

Venous Thrombosis and Pulmonary Embolism Treatment with Rivaroxaban

Infectious Waste Management Plan

Quality Requirements of a Point of Care Testing Service

DACUM Research Chart for Medical Office Assistant

FAQs about Warfarin (brand name Coumadin )

Content Sheet 16-1: Introduction to Documents & Records

2.3. The management in each HCF shall be responsible for ensuring good waste management practices in their premises.

MOUNT SINAI SCHOOL OF MEDICINE. Chemical Storage Practices

Contents. POCT Program Massachusetts General Hospital - Pathology Service 55 Fruit Street, Boston, MA 02114

MOHS MICROGRAPHIC SURGERY

OBJECTIVES: Visitors learn what an antioxidant is and how it behaves. They also learn how to test for the presence of vitamin C..

Hemoglobin Testing using the Data Management HemoCue Analyzer

THE UNIVERSITY OF MAINE BIOMEDICAL WASTE MANAGEMENT PLAN

CHM220 Addition lab. Experiment: Reactions of alkanes, alkenes, and cycloalkenes*

The faecal occult blood (FOB) test

Arthritis

Quality Assurance Guidelines for Testing Using Rapid HIV Antibody Tests Waived Under the Clinical Laboratory Improvement Amendments of 1988

Medicare. Orientation Guide

Cost Sharing Definitions

LABORATORY PROCEDURE MANUAL

PROCEDURE NO. POC LBH. Printed copies are for reference only. Please refer to the electronic copy for the latest version.

GASTRIC BYPASS SURGERY CONSENT FORM

MATERIAL SAFETY DATA SHEET

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Learning Objectives. Introduction to Medical Careers. Vocabulary: Chapter 16 FACTS. Functions. Organs. Digestive System Chapter 16

How does escreen bring automation to DOT program management?

POC.PC.17 Point of Care Testing AMNISURE PROCEDURE FOR RUPTURED FETAL MEMBRANES TABLE OF CONTENTS. 1.0 Principle of Procedure.. 2

Juice Titration. Background. Acid/Base Titration

Community Center Readiness Guide Additional Resource #17 Protocol for Physician Assistants and Advanced Practice Nurses

Acids and Bases. AND a widemouth container of the following solids:

BioResearch. RAFT 3D Cell Culture Kit Protocol

Preventive services process, Nightingale on Demand EMR. Entering data consistently and generating reminder letters with MD verification

Air Quality Performance Test Guidelines. Kansas Department of Health and Environment Bureau of Air and Radiation

UNITED WORLD LIFE INSURANCE COMPANY OMAHA, NEBRASKA A Mutual of Omaha Company OUTLINE OF MEDICARE SUPPLEMENT COVERAGE COVER PAGE

Content Sheet 5-1: Overview of Sample Management

Document and Record Control in a Hospital Clinical Laboratory

HiPer Immunoelectrophoresis Teaching Kit

Transcription:

POCT Program Massachusetts General Hospital - Pathology Service 55 Fruit Street, Boston, MA 02114 Title: Hemoccult Sensa Fecal Occult Blood Procedure Cross References: Hemoccult Sensa Fecal Occult Blood Training and Competency Record Hemoccult Sensa Outpatient Patient Result-QC log Hemoccult Sensa Patient Care Services QC Log Hemoccult Sensa Slides and Developer Lot Documentation MGH POCT QC Storage Ordering and Documentation Guide Hemoccult Sensa Job Aid Contents Purpose... 2 Scope... 2 Policy and Procedure Statement... 2 Regulatory Requirements... 2 Critical Elements... 3 Limitations/Interferences... 3 Test Kit/Supplies/Equipment... 3 Storage and Stability... 4 Specimen Collection... 4 Test Procedure... 4 Interpretation of the Hemoccult Sensa Test... 4 Performance Monitor Feature (Quality Control Monitoring)... 5 Hemoccult Sensa Slides and Developer Lot Documentation... 5 Reference Range... 5 Documentation... 5 Training/Competency Assessment... 6 References... 6 Cross - References... 6 Approved by: Kent Lewandrowski, M.D. 6/1/2005 Written/Updated by: Gino Pagnani Date: 4/3/09 1

Purpose This document outlines policies and procedures that deal with fecal occult blood testing. In an effort to be concise, some information may be excluded from the manufacturer s recommended procedure. It is recommended that operators familiarize themselves with the manufacturer s product information that accompanies each package and their manual if one exists. Scope Level of Personnel: All RNs, NPs, PCAs, MAs, who have successfully completed initial training and maintained annual competency. Testing Site: All sites approved and on file with the Department of Pathology s POCT Division. Policy and Procedure Statement Hemoccult Sensa Test Kits are used as a routine colo-screening test for the qualitative detection of fecal occult blood, which may be an indication of gastrointestinal disease. It is NOT a test for colorectal cancer or other specific diseases. The manufacturer recommends this test for professional use as a diagnostic aid during routine physical exams for hospital patients, to monitor bleeding in patients with iron deficiency anemia or recuperating from surgery, peptic ulcer, ulcerative colitis and other conditions, and screening programs for colorectal cancer when Patient Instructions are followed (See Manufacturers Product Instructions). Additional information can be found on the manufacturer s insert provided with each box of slides. Regulatory Requirements I. Each testing site must have a documented quality control program, which is developed in collaboration with or has been approved by the MGH Pathology Service. II. All test results must be maintained in patient records with all required information for four years Required information: 1. Patient s name 2. Medical Record Number 3. Patient s gender 4. Patient s age or date of birth 5. Date & time test collected, performed and reported 6. Ordering Physician 7. Responsible physician (if not 6) 8. Reference or Target Range 9. Test Performed 10. Test units 11. Lab name III. Additional information that must be retained for four years: 1. Testing personnel records 2. Quality control results 3. Product information (i.e. serial number, lot numbers, expiration dates, etc.), information on quality control and any remedial action 4. QC charts, maintenance sheets, reference and critical ranges IV. Other 1. Universal precautions must be observed when handling any patient specimen. 2. A physician s order or standing order is required prior to performing test. 2

3. The Hospital Hand Hygiene policy must be adhered to at all times. Critical Elements 1. The On Slide Performance Monitor is performed on each slide after patient testing. 2. Do not use Hemoccult Sensa testing for gastric testing. 3. Only approved lots obtained through Materials Management/O&M may be used with this procedure. Limitations/Interferences Interfering substances In general, patients should be carefully instructed to not ingest foods and vitamins that can cause false positive or false-negative test results for at least 72 hours before and through the test period. 1. Substances that can cause false-positive test results: Red meat (beef, lamb, and liver) Aspirin (greater than 325 mg/day) and other non-steroidal anti-inflammatory drugs such as ibuprofen, indomethacin and naproxen Corticosteroids, phenylbutazone, reserpine, anticoagulants, antimetabolites, and cancer chemotherapeutic drugs Alcohol in excess The application of antiseptic preparations containing iodine (povidone/iodine mixture) A high bile content may cause the feces to appear green. A distinct green color (no blue), appearing on or at the edge of the smear within 60 seconds after adding the developer, should be interpreted as negative for occult blood. Dietary iron supplements will not produce false-positive test results with Hemoccult SENSA tests. Acetaminophen is not expected to affect test results. 2. Substances that can cause false-negative test results: Ascorbic acid (vitamin C) in excess of 250 mg per day Excessive amounts of vitamin C-enriched foods such as citrus fruits and juices Iron supplements which contain quantities of vitamin C in excess of 250 mg per day Occasionally, a light blue discoloration may be noticed on the guaiac test paper. This discoloration does not affect the accuracy or performance of the test when it is developed and interpreted according to the recommended procedure. When developer is added directly over the fecal smear on a discolored slide, the blue background color migrates outward and a blue ring forms at the edge of the wetted area, leaving the guaiac paper around the fecal smear off-white in color. Any blue on or at the edge of the smear is positive for Hemoccult blood. Test Kit/Supplies/Equipment Products Vendor Manufacturer # Instant-Recall Memory Timer Fisher Scientific People Soft# Fisher #: 02-401-7 Storage Comments Hemoccult Sensa Slide Hemoccult Sensa Developer O&M# 5891-64151PHC O&M# 5891-64115PHC 64151PHC 20363 RT (15-30 C,59-86 F) 64115PHC 20374 RT (15-30 C,59-86 F) Packaged as single cards no developer Individual bottles of developer Hemoccult Sensa Dispensapak Plus O&M# 5891-64130PHC 64130PHC 028114 RT (15-30 C,59-86 F) Packaged as triple card sets for patient home use; has two bottles of developer 3

Materials supplied in the Hemoccult Sensa DIspensapak Plus: 1. Hemoccult SENSA Slides (blue striped) 2. Hemoccult SENSA Developer (blue cap and striped label) 3. Applicator sticks 4. Patient envelopes with patient sample collection instructions (Hemoccult SENSA Dispensapak Plus) 5. Mailing pouch for returning slides (Hemoccult SENSA Dispensapak Plus) 6. Collection tissues (Hemoccult SENSA Dispensapak Plus) 7. Hemoccult SENSA product instructions Storage and Stability Do not refrigerate or freeze. Slides should be protected from extreme heat and light or volatile chemicals (e.g., iodine, chlorine, bromine, or ammonia. The Hemoccult Sensa Slides and Developer will remain stable until the expiration dates which appear on each slide and developer bottle when stored as recommended appear on each slide and developer bottle when stored as recommended. Specimen Collection Label fecal occult blood card with two patient identifiers per hospital policy. Collect a small fecal sample on the end of applicator stick. Test Procedure Check the expiration date of the developer before using. 1. Identification (two identifiers required): Before opening the slide label with patient s name and/or date of birth and patient medical record number 2. Follow hand hygiene protocol and put on gloves. 3. Preparing the Test: Using applicator provided, collect small fecal sample. Apply a THIN smear inside Box A with the applicator stick Reuse applicator to obtain second sample from a different part of feces Apply thin smear covering Box B Close cover flap. Dispose of applicator in waste container. 4. Developing the Test: 5. Wait 3-4 minutes before applying the developer Using applicator provide 6. Open flap on backside of slide and apply 2 drops of Hemoccult Sensa Developer to the guaiac paper directly over each smear. Read patient results within 60 seconds! Interpretation of the Hemoccult Sensa Test 1. Negative Smears (fig. 1) Applicator stick No detectable blue on or at the edge of the smears indicates the test is negative for occult blood. 2. Positive Smears (fig. 2) Any trace of blue on or at the edge of one or more of the smears indicates the test is positive for occult blood. Negative (fig.1) Positive (fig.2) 4

Do not report any results unless the On Slide Performance Monitor produces an acceptable result. Document the Performance Monitor results on the Patient/Quality Control log sheet. Performance Monitor Feature (Quality Control Monitoring) The function and stability of the slides and developer must be tested using the On Slide Performance Monitor (fig. 4). It is performed on EVERY SLIDE as part of the test procedure. The positive (+) and negative (-) Performance Monitor areas are located under the sample area on the developing side of the slides. Procedure to develop performance monitor: 1. Apply ONE DROP ONLY of Hemoccult Sensa Developer BETWEEN the (+) and (-) Performance Monitor areas. 2. Read the Performance Monitor results within 10 seconds: a BLUE color will appear in the (+) area, and NO BLUE will appear in the (-) area if the kit is functional. 3. If neither occurs, discard the slide and repeat the test using another slide. If the problem reoccurs, try the following: Repeat the test using a new developer Repeat the test using a card and developer from a new box (verifying first that it is an approved lot). Notify the POCT Coordinators at 6-1462 or 3-5392. Positive: A blue color will appear within 10 seconds after application of developer and remain stable for at least 60 seconds if the test system is functional. The positive Performance Monitor area contains a hemoglobin-derived catalyst, which will turn blue within 10 seconds after applying developer. Negative: No blue color should appear after application of developer if the test system is functional. The negative performance Monitor area contains no such catalyst and should not turn blue after applying developer. On Slide Performance Monitor (fig. 4). Any blue originating from the Performance Monitor areas should be ignored when reading the specimen test results. Neither the intensity nor the shade of the blue from the positive Performance Monitor areas, as illustrated, should be used as a reference for the appearance of positive test results. The Performance Monitor feature provides assurance that the fecal occult blood paper and developer are functional. In the unlikely event that the Performance Monitor areas do not react as expected after applying developer, the results should be regarded as invalid. Should this occur, contact the POCT Coordinators at 3-5392 or 6-1462. Only those patient results that have demonstrated acceptable On Slide Performance are to be accepted and acted upon. The Performance monitor results must be documented concurrently on the patient s chart or the QC log sheet. Hemoccult Sensa Slides and Developer Lot Documentation A single lot of slides and developer is sequestered at Owens and Minor for use at MGH. When a new lot is received, the POCT Coordinators are notified. The procedural controls on the Hemoccult cards are documented with each test and are considered the same as external controls. External validation of the cards is not required. Reference Range Patient test: Negative Documentation The patient s results and the Performance monitor results must be recorded concurrently in one of the following manners: 5

1. in the patient s record, or 2. on Fecal Occult Blood Patient/ QC log or 3. on another approved permanent record. All records must be retained and retrievable for 4 years. Training/Competency Assessment Competency is assessed after initial training and annually using at least two of the following methods: 1. Performing a test on a blind specimen. 2. Supervisor observes performance of routine work. 3. Each user s quality control performance is monitored. 4. Written testing specific to the method. References Hemoccult Sensa Slide package insert. Beckman Coulter Inc. 4300 N. Harbor Blvd. Fullerton, CA 92834-3100 www.beckmancoulter.com/pcd Cross - References Hemoccult Sensa Fecal Occult Blood Training and Competency Record Hemoccult Sensa Slides and Developer Lot Documentation Hemoccult Sensa Slides Outpatient Result-Quality Control Log Hemoccult Sensa Patient Care Services QC Log 6